Inhibikase Therapeutics, Inc. (IKT)
NASDAQ: IKT · Real-Time Price · USD
1.670
-0.040 (-2.34%)
Sep 5, 2025, 4:00 PM - Market closed

Inhibikase Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 20202017 - 2020
Period Ending
Jun '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2017 - 2020
--0.260.123.10.7
Upgrade
Revenue Growth (YoY)
--111.03%-96.02%343.92%-37.79%
Upgrade
Cost of Revenue
27.1717.2113.6212.0311.360.89
Upgrade
Gross Profit
-27.17-17.21-13.36-11.91-8.26-0.2
Upgrade
Selling, General & Admin
18.5411.386.736.226.512.62
Upgrade
Operating Expenses
17.0211.386.736.226.512.62
Upgrade
Operating Income
-44.19-28.59-20.09-18.13-14.77-2.82
Upgrade
Interest Expense
-----0.02-0.03
Upgrade
Interest & Investment Income
2.681.071.060.07--
Upgrade
Pretax Income
-41.5-27.52-19.03-18.05-14.79-2.85
Upgrade
Net Income
-41.5-27.52-19.03-18.05-14.79-2.85
Upgrade
Net Income to Common
-41.5-27.52-19.03-18.05-14.79-2.85
Upgrade
Shares Outstanding (Basic)
65246431
Upgrade
Shares Outstanding (Diluted)
65246431
Upgrade
Shares Change (YoY)
893.41%293.35%42.74%39.15%121.72%0.39%
Upgrade
EPS (Basic)
-0.64-1.16-3.16-4.28-4.87-2.08
Upgrade
EPS (Diluted)
-0.64-1.16-3.16-4.28-4.87-2.08
Upgrade
Free Cash Flow
-19.92-19.15-18.1-17.59-14.3-1.13
Upgrade
Free Cash Flow Per Share
-0.31-0.81-3.00-4.17-4.71-0.82
Upgrade
Gross Margin
-----266.35%-27.97%
Upgrade
Operating Margin
---7711.98%-14686.17%-476.23%-403.52%
Upgrade
Profit Margin
---7304.73%-14625.86%-476.88%-407.73%
Upgrade
Free Cash Flow Margin
---6947.87%-14253.37%-461.10%-161.69%
Upgrade
EBITDA
-44.14-28.56-19.91-18.12--
Upgrade
D&A For EBITDA
0.050.030.180.01--
Upgrade
EBIT
-44.19-28.59-20.09-18.13-14.77-2.82
Upgrade
Revenue as Reported
--0.260.123.10.7
Upgrade
Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q